ReviewCurrent opinion in rheumatology2025
Harnessing artificial intelligence to advance insights in systemic sclerosis skin and lung disease.
Review in Current opinion in rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
purpose of reviewThe purpose of this review is to summarize the uses of artificial intelligence for advancing systemic sclerosis (SSc) skin and lung disease research through 2024. RECENT
findingsApplications of AI in SSc research have expanded markedly in recent years. The most common artificial intelligence method identified was supervised machine learning for predictive modeling. Supervised machine learning uses input data labeled with a known outcome to train a model to predict outcomes when encountering new data. Using machine learningassisted feature selection and posttraining feature importance techniques also highlighted key predictors within complex datasets, informing possible mechanisms underlying heterogeneous patient outcomes. Additionally, unsupervised machine learning approaches have been used to identify patient subsets with distinct clinical trajectories. Unsupervised machine learning identifies groups with similar characteristics within a dataset, without considering a specific outcome. Digital image analysis using deep learning has also been undertaken in lung imaging studies to quantify interstitial lung disease (ILD) extent and automate ILD subtype classification, as well as skin biopsy analysis to quantify histologic changes. These scalable tools could efficiently automate prognostic assessments for use across centers of varying local expertise. SUMMARY: Artificial intelligence represents a tool for analyzing high-dimensional, complex datasets to derive robust results, even within relatively small SSc cohorts. To date, artificial intelligence driven insights to SSc skin and lung disease have focused on identifying patient subsets, quantifying disease severity, and building predictive models to inform personalized patient care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.